Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure

NCT04385823 | Completed

• 1 other identifier: HLM_JDR9
• Study Type: observational
• Target: 62
• Locations: 1 country
• Sites: 1

Brief Summary

Nasal High Flow oxygen therapy (NHF) is commonly used as first line ventilatory support in patients with acute hypoxemic respiratory failure (AHRF). It's use has been initially limited in Covid-19 patients presenting with AHRF. The aim of the study is to describe the use of NHF in Covid-19-related AHRF and report the changes in the respiratory-oxygenation index (termed ROX index) over time in these patients.

Conditions

Respiratory Syndrome, Acute, Severe; Hypoxic Respiratory Failure; Viral Pneumonia

Outcome Measures

Primary Outcomes (1)

• Changes in ROX index

  values of ROX index during ICU stay

  from date of NHF initiation until date of weaning from NHF or date of intubation whichever came first, assessed up to 2 months

Secondary Outcomes (7)

• NHF failure

  from date of NHF initiation until date of weaning from NHF or date of intubation whichever came first, assessed up to 2 months

• NHF flow

  from date of NHF initiation until date of weaning from NHF or date of intubation whichever came first, assessed up to 2 months

• NHF inspired fraction in oxygen

  from date of NHF initiation until date of weaning from NHF or date of intubation whichever came first, assessed up to 2 months

• oxygenation

  from date of NHF initiation until date of weaning from NHF or date of intubation whichever came first, assessed up to 2 months

• respiratory status

  from date of NHF initiation until date of weaning from NHF or date of intubation whichever came first, assessed up to 2 months

Interventions

patients receiving nasal high flow DEVICE

patients admitted to the ICU for Covid-19-related acute hypoxemic respiratory failure treated with nasal high flow

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

all adult patients admitted to the ICU with proven Covid-19 pneumonia and acute hypoxemic respiratory failure requiring supplemental oxygen administered via NHF

You may qualify if:

• Covid-19 pneumonia
• acute hypoxemic respiratory failure
• need for nasal high flow therapy as first line therapy
• admission to intensive care

You may not qualify if:

• intubation prior to NHF therapy

Sponsors & Collaborators

• Hôpital Louis Mourier: lead

Study Sites (1)

Hôpital Louis Mourier, Assistance Publique - Hôpitaux de Paris

Colombes, 92700, France

Location

Related Publications (2)

• Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernandez G, Garcia-de-Acilu M, Frat JP, Masclans JR, Ricard JD. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy. Am J Respir Crit Care Med. 2019 Jun 1;199(11):1368-1376. doi: 10.1164/rccm.201803-0589OC.

  PMID: 30576221 BACKGROUND

• Roca O, Messika J, Caralt B, Garcia-de-Acilu M, Sztrymf B, Ricard JD, Masclans JR. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. J Crit Care. 2016 Oct;35:200-5. doi: 10.1016/j.jcrc.2016.05.022. Epub 2016 May 31.

  PMID: 27481760 BACKGROUND

MeSH Terms

Conditions

Severe Acute Respiratory Syndrome; Pneumonia, Viral

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Pneumonia; Lung Diseases

Study Officials

• Jean-Damien Ricard, MD, PhD

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head Medico-surgical ICU

Study Record Dates

• First Submitted: May 11, 2020
• First Posted: May 13, 2020
• Study Start: March 1, 2020
• Primary Completion: May 4, 2020
• Study Completion: May 4, 2020
• Last Updated: May 13, 2020

Record last verified: 2020-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)